Revolution

Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline includes RAS(ON) inhibitors designed to inhibit various oncogenic variants of the RAS protein, as well as RAS companion inhibitors for combination treatment strategies.